Pharmaceutical Technology

OCTOBER 6, 2022

Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. . This trial will evaluate the safety of the vaccine and generate efficacy data.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

OCTOBER 5, 2022

Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium. At the moment most cases are treated with azithromycin, with intravenous ceftriaxone generally reserved as a last-line therapy.

Vaccination 98

Vaccination Vaccine Immune Response Bacterium 98